

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited
先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

**VOLUNTARY ANNOUNCEMENT IN RELATION TO
THE CLINICAL TRIAL APPROVAL FOR SIM-307
ISSUED BY THE CENTER FOR DRUG EVALUATION
OF NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC**

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on April 12, 2021, SIM-307 as an innovative drug pipeline product of the Company, has obtained the clinical trial approval issued by the National Medical Products Administration, PRC (中華人民共和國國家藥品監督管理局). SIM-307 is an Aquaporin-4 (AQP4) inhibitor developed based on the Aquaporin water channel theory which has been awarded the Nobel Prize. It is administered intravenously and intended for the treatment of acute severe ischaemic stroke complicated by cerebral oedema, as a first-in-class small molecule drug with a novel mechanism of action for brain oedema therapy.

The Company entered into a license agreement with Aeromics, Inc. (“**Aeromics**”) in October 2019, pursuant to which the Company has obtained a proprietary and sublicensable license for its self-funded research, development, production and commercialization of SIM-307 in the Greater China region. Aeromics has completed the phase I clinical trial of SIM-307 in the U.S..

ABOUT THE COMPANY

The Company is a company engaged in the R&D, production and commercialization of pharmaceuticals with the national key laboratory of translational medicine and innovative pharmaceuticals. The Company has a diversified product portfolio in strategically focused therapeutic areas, including, (i) oncology, (ii) central nervous system diseases and (iii) autoimmune diseases, with leading positions in their respective therapeutic segments and/or established track record. The Company continues to source innovative therapies globally and established extensive strategic partnership with several multinational companies.

By order of the Board
Sincere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and executive Director

Hong Kong, April 13, 2021

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. WAN Yushan and Mr. TANG Renhong as the executive Directors; Mr. ZHAO John Huan as the non-executive Director; and Mr. SONG Ruilin, Mr. WANG Jianguo and Mr. WANG Xinhua as the independent non-executive Directors.